JP2016535780A5 - - Google Patents

Download PDF

Info

Publication number
JP2016535780A5
JP2016535780A5 JP2016552432A JP2016552432A JP2016535780A5 JP 2016535780 A5 JP2016535780 A5 JP 2016535780A5 JP 2016552432 A JP2016552432 A JP 2016552432A JP 2016552432 A JP2016552432 A JP 2016552432A JP 2016535780 A5 JP2016535780 A5 JP 2016535780A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
patient
ferric citrate
kidney disease
chronic kidney
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016552432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535780A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/063643 external-priority patent/WO2015066593A1/en
Publication of JP2016535780A publication Critical patent/JP2016535780A/ja
Publication of JP2016535780A5 publication Critical patent/JP2016535780A5/ja
Pending legal-status Critical Current

Links

JP2016552432A 2013-11-04 2014-11-03 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄 Pending JP2016535780A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
US61/899,866 2013-11-04
PCT/US2014/063643 WO2015066593A1 (en) 2013-11-04 2014-11-03 Ferric citrate for reducing cardiac failure in chronic kidney disease patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019140640A Division JP6828100B2 (ja) 2013-11-04 2019-07-31 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄

Publications (2)

Publication Number Publication Date
JP2016535780A JP2016535780A (ja) 2016-11-17
JP2016535780A5 true JP2016535780A5 (https=) 2017-12-14

Family

ID=53005244

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016552432A Pending JP2016535780A (ja) 2013-11-04 2014-11-03 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄
JP2019140640A Active JP6828100B2 (ja) 2013-11-04 2019-07-31 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄
JP2021007091A Pending JP2021073230A (ja) 2013-11-04 2021-01-20 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019140640A Active JP6828100B2 (ja) 2013-11-04 2019-07-31 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄
JP2021007091A Pending JP2021073230A (ja) 2013-11-04 2021-01-20 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄

Country Status (15)

Country Link
US (3) US20160256486A1 (https=)
EP (2) EP3747432A1 (https=)
JP (3) JP2016535780A (https=)
KR (1) KR102392441B1 (https=)
CN (1) CN105873583A (https=)
AU (1) AU2014341975A1 (https=)
BR (1) BR112016009901A8 (https=)
CA (1) CA2928200A1 (https=)
EA (1) EA201690926A1 (https=)
HK (1) HK1223031A1 (https=)
IL (1) IL245317A0 (https=)
MX (1) MX2016005734A (https=)
SG (1) SG11201603091QA (https=)
TW (2) TWI744215B (https=)
WO (1) WO2015066593A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011011541A1 (en) 2009-07-21 2011-01-27 Henry Trong Le Ferric citrate dosage forms
EP3003327B1 (en) 2013-06-05 2017-08-09 Tricida Inc. Proton-binding polymers for oral administration
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
RS61409B1 (sr) 2014-12-10 2021-03-31 Tricida Inc Polimeri koji vezuju protone za oralnu primenu opis
CN109414453B (zh) 2016-05-06 2023-02-17 特里赛达公司 用于治疗酸碱失衡的组合物
CA3080651A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
MX2021004640A (es) 2018-10-29 2021-05-28 Pharmacosmos Holding As Tratamiento de la deficiencia de hierro con carboximaltosa ferrica.
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
EP4347022A1 (en) * 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (https=) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
CA2619591C (en) * 2005-08-18 2020-03-24 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
KR20080106506A (ko) * 2006-01-30 2008-12-08 글로보아시아 엘엘씨 만성 신장병의 치료 방법
JP2009525277A (ja) * 2006-01-30 2009-07-09 グロボアジア エルエルシー 軟組織石灰化の回復、予防、遅延または安定化方法
WO2011011541A1 (en) * 2009-07-21 2011-01-27 Henry Trong Le Ferric citrate dosage forms
WO2012006473A1 (en) * 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US20130345303A1 (en) * 2012-06-21 2013-12-26 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of chronic kidney disease patients

Similar Documents

Publication Publication Date Title
JP2016535780A5 (https=)
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
JP2016519107A5 (https=)
JP2016516751A5 (https=)
JP2016510326A5 (https=)
JP2015522603A5 (https=)
JP2014513121A5 (https=)
JP2013523758A5 (https=)
De Caridi et al. Effectiveness of prostaglandin E1 in patients with mixed arterial and venous ulcers of the lower limbs
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
JP2016538288A5 (https=)
JP2017061488A5 (https=)
MX2018011293A (es) Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma.
JP2017511307A5 (https=)
Félix et al. Warfarin-induced gastric intramural hematoma
Send et al. Multiple causes for rhinolithiasis
WO2018051295A3 (en) Non-saponifiable compounds of natural lipids for use in the treatment of tumour pathologies
Pinero-Saavedra DRESS syndrome in an elderly patient: case report
Glezer et al. Decrease in heart rate in patients with coronary artery disease and chronic heart failure the purpose and means
JP2019529554A5 (https=)
WO2018051294A3 (en) Non—saponifiable compounds of natural lipids for use in the treatment of cardiac pathologies
Protasov et al. The effectiveness of moxonidine in patients with uncomplicated hypertensive crisis
JP2019504085A5 (https=)
Adamyan et al. Spironolacton reduces left ventricular diastolic stiffness, remodeling and improves functional status in hypertensive patients with preserved ejection fraction heart failure
Torihashi Warfarin/heparin